<b>Background/Objective:</b> Breast cancer (BC) management has traditionally relied on static clinicopathologic and immunohistochemical biomarkers (hormone receptor status, HER2 expression, and proliferative activity assessed at diagnosis). This evidence concerns the gene NR4A1 and breast cancer.